Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13107
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, M. K. Y.-
dc.contributor.authorTatian, A.-
dc.contributor.authorSebaratnam, D. F.-
dc.date.accessioned2024-12-11T00:34:10Z-
dc.date.available2024-12-11T00:34:10Z-
dc.date.issued2024-
dc.identifier.issn21686068 (ISSN)-
dc.identifier.urihttps://swslhd.intersearch.com.au/swslhdjspui/handle/1/13107-
dc.publisherAmerican Medical Association-
dc.subjectberemagene geperpavec adolescent adult caregiver child drug cost epidermolysis bullosa dystrophica health care access health care cost human Letter quality of life sensitivity analysis article clinical article female-
dc.titleEstimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-
dc.typeJournal Article-
dc.description.affiliatesRoyal Prince Alfred Hospital, Camperdown, NSW, Australia Department of Dermatology, Liverpool Hospital, Liverpool, NSW, Australia Sydney Children's Hospital, Randwick, NSW, Australia Faculty of Medicine and Health, University of New South Wales, NSW, Australia-
dc.identifier.doi10.1001/jamadermatol.2024.2999-
dc.type.studyortrialLetter-
dc.identifier.journaltitleJAMA Dermatology-
Appears in Collections:Liverpool Hospital

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing